Juntos: A Pilot Test of a Dating Violence Intervention for Latine Families

July 3, 2026 updated by: Maya Ragavan, University of Pittsburgh

Juntos Latine Dating Violence Prevention Intervention Pilot

In this trial, we will be pilot-testing a family-based dating violence prevention program for Latine caregivers and adolescents. Participants will be randomized 1:1 to receive a community-based 6 week intervention or to a wait-list control where they will receive a resource guide.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
41

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • Primary Care Center
      • Pittsburgh, Pennsylvania, United States, 15216
        • Casa San Jose

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Adolescents

  1. Between the ages of 12-16
  2. Identify as Hispanic or Latino/a/x/e
  3. Speaks Spanish or English
  4. Lives within 50 miles of Pittsburgh, Pennsylvania
  5. Has a participating parent or caregiver* in the study

Adults

  1. Over the age of 18
  2. Identifies as Hispanic or Latino/a/x/e
  3. Speaks Spanish
  4. Lives within 50 miles of Pittsburgh, Pennsylvania
  5. Is a caregiver of a participating adolescent in the study
  6. Was born outside of the United States

Exclusion Criteria:

  • Does not meet inclusion criteria
  • Unable to consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Juntos intervention
In the Juntos intervention, 24 caregiver-adolescent dyads will receive a 6 week family-based dating violence prevention intervention called Juntos. Juntos includes 6 in-person sessions and 5 at home activities and was developed by Latino caregiver-adolescent dyads. Topics include cultural values and practices, talking about dating and dating violence, rule-setting, understanding signs of healthy and unhealthy relationships, and resources for support.
Behavioral: Juntos
6 week family-based intervention
Active Comparator: Control group
The control arm will resource a resource guide and can be placed on a wait list to receive the intervention after the intervention is complete
Behavioral: Resource guide
Active control arm will receive a resource guide

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Acceptability
Time Frame: weekly for 6 weeks, after each intervention session
Acceptability Intervention Measure (scored on a Likert scale, 1 to 5 with 1 being completely disagree and 5 being completely agree). 4 items will be averaged for a summary score with higher numbers meaning higher acceptability.
weekly for 6 weeks, after each intervention session
Feasibility
Time Frame: baseline (pre-intervention), 1 week post-intervention follow up, 3 month post-intervention follow up surveys
%participants who are enrolled, %consented, % randomized, % completed baseline, follow up and 3 month follow up surveys
baseline (pre-intervention), 1 week post-intervention follow up, 3 month post-intervention follow up surveys

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Self-efficacy in preventing dating violence
Time Frame: baseline (pre-intervention), 1 week post-intervention follow up, 3 month post-intervention follow up surveys
11 item measure scored on a Likert scale to assess self-efficacy in preventing dating violence. Score for 7 items is on a 4 point Likert scale with 1: not at all confident and 4: very confident and the score for the other 3 items is 1 to 5 with 1: strongly disagree and 5: strongly agree. We will create a summary score which is the average of these 7 items, with higher numbers meaning higher self-efficacy around preventing dating violence.
baseline (pre-intervention), 1 week post-intervention follow up, 3 month post-intervention follow up surveys
Motivation to preventing dating violence
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
4 item measure scored on Likert scale focused on motivation caregivers and adolescents have around preventing dating violence. 0=not at all important and 10=very important. We will great a summary score which is an average of the 4 items, with a higher score indicating higher motivation around preventing dating violence.
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Attitudes around dating violence
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
12 item measure assessing participants' attituding around dating violence scored on a Likert scale. 1: Not abusive: 2: a little abusive; 3: somewhat abusive; 4: very abusive; 5: extremely abusive. We will create a summary score which is an average of the 12 items, which higher scores indicating believing that the behaviors are more abusive
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Caregiver-adolescent communication around dating violence
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
5 item measure scored on Likert scale assessing communication around dating violence. 0: never; 1: once; and 2: more than once. We will create a summary scare which is an average of the 5 items with higher numbers indicating more conversations.
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Parental monitoring
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Scale around dating and dating violence specific parental monitoring. This scale includes 6 items around time and resources scores on a 5 point Likert scale with 1: strongly disagree to 5: strongly agree; 2 items around parental knowledge of child's dating partner which is scored on a 5 point Likert scale with 1: strongly disagree and 5: strongly agree; 3 items around dating rule setting which is score on a 5 point Likert scale from 1: strongly disagree to 5: strongly agree and 4 items around child disclosure of dating violence scored on a 5 point Likert scale from 1:strongly disagree to 5; strongly agree. We will great a summary scale which is the average of the measures, with higher numbers indicating more parental monitoring.
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Adolescent relationship abuse victimization (whether someone has experienced violence)
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
25 item measure to assess experiences of physical, emotional, sexual, economic, and digital dating violence (0=never experienced; 1=experienced but not in the last year; and 2=experienced in the last year)
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Adolescent relationship abuse perpetration (whether someone has used violence)
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
25 item measure to assess experiences of physical, emotional, sexual, economic, and digital dating violence perpetration (0=never experienced; 1=experienced but not in the last year; and 2=experienced in the last year)
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Ethnic Identity
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Multiethnic Identity Measure; 12 item scale on a 4 point Likert scale from 1: strongly disagree to 4: strongly agree. Summary score of the average of 12 items with higher scores indicating more ethnic identity.
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Acculturation conflict measure
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
7 item acculturation conflict measure (investigator developed) scored on a 4 point Likert Scale from 1: strongly disagree to 4: strongly agree. A summary score of the average of the 7 items will be computed, with higher scores indicating more parent-adolescent acculturation conflict.
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
Discrimination Scale
Time Frame: baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys
9 item Everyday Discrimination Scale scored on a 6 point Likert scale with 1: never to 6: every day. A summary score (average of the 9 items) will be created with higher scores indicating more experiences of discrimination.
baseline (pre-intervention), 1-week post intervention follow up, 3 month post-intervention follow up surveys

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Pittsburgh

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 30, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 1, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 4, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 28, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • STUDY24020165
  • K23HD104925 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Due to the sensitivity of the survey data, we will not share individual patient data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings